Noom, which makes an app to help people lose weight by changing their behavior, raises $540M, sources say at a $3.7B valuation; Noom had sales of $400M in 2020
Context & Ripple Effects
Noom's raise is a step change from its last round: the company went from a $58M Series E led by Sequoia in May 2019 to $540M at a reported $3.7B valuation two years later, implying roughly a 9x multiple on its $400M of 2020 sales.
The round lands mid-way through a funding wave in digital weight and nutrition care — UK rival Oviva raised an $80M Series C months later, and Found raised a $100M Series B that December — with capital chasing apps that pair software with human or clinical support.
First-order effects
- Noom gets a war chest to scale its direct-to-consumer behavior-change program beyond the $400M revenue base, with Sequoia's earlier bet marked up to one of the largest valuations in the category.
- The $3.7B price sets a public benchmark for weight-care startups: Found's $600M valuation and Oviva's raise now price against Noom's numbers when they court their own investors.
Second-order effects
- Competitors differentiate away from Noom's playbook rather than into it — Oviva leans on personalized diet advice in European markets while Found positions as medication-inclusive weight care, splitting the category Noom dominated.
- Investors extend the thesis downstream to clinically anchored models, culminating in Nourish's insurance-covered dietitian platform reaching a $1B+ valuation, signaling payers rather than consumers as the next funding story.
Third-order effects
- Noom itself later laid off about 500 people, mostly coaches, suggesting the high-valuation, human-coaching-heavy consumer model struggled to justify its multiple — pushing the category toward payer-funded, clinician-delivered care.
- If the pattern holds, digital weight care consolidates around whichever players convert consumer subscriptions into reimbursable medical services, leaving pure subscription apps exposed.
The trend: Consumer behavior-change health apps are cycling from mega consumer rounds toward insurer-reimbursed clinical delivery, with Noom's $3.7B peak marking the top of the first phase.